-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascelia Pharma publishes Orviglance liver MRI contrast agent study in JMRI

PUBT·09/24/2026 05:30:30
Listen to the news
Ascelia Pharma publishes Orviglance liver MRI contrast agent study in JMRI
  • Ascelia Pharma announced publication of a peer-reviewed Orviglance clinical study in the Journal of Magnetic Resonance Imaging.
  • Results were already presented via the journal article, not flagged for a future medical meeting.
  • Study assessed a single oral dose in adults with hepatic impairment versus those without impairment.
  • Publication supports Orviglance’s differentiated profile as a manganese-based liver MRI contrast agent, reinforcing its clinical development rationale.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascelia Pharma AB published the original content used to generate this news brief on September 24, 2026, and is solely responsible for the information contained therein.